Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Monson, Nancy L ^a,b   Cravens, Petra ^a   Hussain, Rehana ^a   Harp, Christopher T ^a   Cummings, Matthew ^a   Martin, Maria de Pilar ^a   Ben, Li Hong ^a   Do, Julie ^a   Lyons, Jeri Anne ^c   Lovette Racke, Amy ^d   Cross, Anne H ^e   Racke, Michael K ^d   Stüve, Olaf ^a,f   Shlomchik, Mark ^g   Eagar, Todd N ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^g YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; INTERLEUKIN 17; RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG RESPONSE; GROWTH INHIBITION; IMMUNOPATHOGENESIS; INFLAMMATORY CELL; LYMPHOCYTE FUNCTION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE; ANIMAL; ANTIBODY SPECIFICITY; AUTOIMMUNITY; C57BL MOUSE; CELLULAR IMMUNITY; DOWN REGULATION; DRUG EFFECT; DRUG SCREENING; IMMUNOLOGY; PATHOLOGY; TRANSGENIC MOUSE;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNITY; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ORGAN SPECIFICITY; T-LYMPHOCYTES;

EID: 79951907091     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017103     Document Type: Article

References (23)

1. Bauman TM, Kasper LH, (2004) Novel approaches and cutting edge immunotherapies in multiple sclerosis. Front Biosci 9: 2302-2322.
2. Menge T, Weber MS, Hemmer B, Kieseier BC, von Budingen HC, et al. (2008) Disease-modifying agents for multiple sclerosis: Recent advances and future prospects. Drugs 68: 2445-2468.
3. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M, (2002) Rituximab: Ongoing and future clinical developmemt. Semin Oncol 29: 105-112.
4. Stuve O, Cepok S, Elias B, Saleh A, Hartung HP, Hemmer B, et al. (2005) Clinical Stabilization and Effective B cell Depletion in the Cerebrospinal Fluid and Peripheral Blood in a Patient with Fulminant Relapsing Remitting Multiple Sclerosis. Arch Neurol In Press.
5. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, et al. (2008) B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676-688.
6. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, et al. (2007) Depletion of B cells in murine lupus: Efficacy and resistance. J Immunol 179: 3351-3361.
7. Eagar TN, Karandikar NJ, Bluestone JA, Miller SD, (2002) The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol 32: 972-981.
8. Martin M, Monson NL, (2007) Potential role of humoral immunity in the pathogenesis of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). Front Biosci 12: 2735-2749.
9. Lyons JA, San M, Happ MP, Cross AH, (1999) B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol 29: 3432-3439.
10. Eagar TN, Turley DM, Padilla J, Karandikar NJ, Tan L, et al. (2004) CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T cell tolerance. J Immunol 172: 7442-7450.
11. Ledbetter JA, Clark EA, (1986) Surface phenotype and function of tonsillar germinal center and mantle zone B cell subsets. Hum Immunol 15: 30-43.
12. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA, (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7: 711-717.
13. Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, et al. (1987) Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69: 584-591.
14. Saville MW, Benyunes MC, Multani PS, (2003) No clinical evidence for CD4+ cell depletion caused by Rituximab. Blood 102: 408; author reply 408-409.
15. del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, et al. (2008) Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 65: 1596-1603.
16. Herrmann P, Schreier MH, Bazin H, Zinkernagel RM, Cerny A, (1988) Delayed type hypersensitivity (DTH) in anti-IgM-treated B cell-depleted mice: Analysis of induction and effector phase. Immunobiology 177: 382-389.
17. (2008) FDA MedWatch Information for Healthcare Professionals Regarding Rituximab and PML.
18. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM, (2002) B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3: 944-950.
19. Mann MK, Maresz K, Shriver LP, Tan Y, Dittel BN, (2007) B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J Immunol 178: 3447-3456.
20. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF, (2008) Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 118: 3420-3430.
21. Weber MS, Prod'homme T, Patarroyo JC, Molnarfi N, Karnezis T, et al. (2010) B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 68: 369-383.
22. Harp CT, Ireland S, Davis LS, Remington G, Cassidy B, et al. (2010) Memory B cells from a subset of treatment-naive relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-gamma production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol 40: 2942-2956.
23. Duddy ME, Alter A, Bar-Or A, (2004) Distinct profiles of human B cell effector cytokines: A role in immune regulation? J Immunol 172: 3422-3427.